A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX nebulizer in patients with pulmonary arterial hypertension

Trial Profile

A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX nebulizer in patients with pulmonary arterial hypertension

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs Iloprost (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 30 Jul 2017 Planned End Date changed from 13 Jul 2017 to 21 Sep 2017.
    • 07 Jul 2017 This trial has been completed in Austria, according to European Clinical Trials Database
    • 05 Mar 2017 Planned End Date changed from 1 Sep 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top